GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline.

The deal gives GSK full ownership of HS235, a clinical-stage, protein-based treatment targeting the activin receptor signalling pathway, a clinically validated target in pulmonary hypertension.

GSK said the candidate is designed with enhanced selectivity and could potentially reduce risks such as bleeding, pericardial effusion and dose-limiting increases in haemoglobin associated with current treatments.